Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ε4

Milica A. Margeta,1 Sophia M. Letcher,1 Robert P. Igo Jr.,2 Jessica N. Cooke Bailey,2,3 Louis R. Pasquale,4 Jonathan L. Haines,2,3 Oleg Butovsky,5,6 and Janey L. Wiggs1; for the NEIGHBORHOOD consortium

1Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, United States
2Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
3Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio, United States
4Department of Ophthalmology, Icahn School of Medicine at Mt. Sinai, New York, New York, United States
5Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
6Evergrande Center for Immunologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States

Correspondence: Milica A. Margeta, Massachusetts Eye and Ear Infirmary, 419 Charles Street, Boston, MA 02114, USA; milica_margeta@meei.harvard.edu.

Received: January 25, 2020
Accepted: May 14, 2020
Published: July 2, 2020

Citation: Margeta MA, Letcher SM, Igo RP Jr., et al. Association of APOE with primary open-angle glaucoma suggests a protective effect for APOE ε4. Invest Ophthalmol Vis Sci. 2020;61(8). https://doi.org/10.1167/iovs.61.8.3

Purpose. Prior studies have demonstrated that microglial activation is involved in the pathogenesis of primary open-angle glaucoma (POAG). Here we sought to identify genetic associations between POAG and variants in APOE and TREM2, genes associated with Alzheimer disease (AD) that critically regulate microglial neurodegeneration-associated molecular signature.

Methods. APOE genotypes were called using imputed data from the NEIGHBOR consortium (2120 POAG cases, 2262 controls) and a second cohort from the Massachusetts Eye and Ear Infirmary (MEEI; 486 cases, 344 controls). TREM2 coding variants were genotyped by means of the Illumina HumanExome BeadArray. The data set was analyzed for association with POAG overall, as well as the high-tension glaucoma (HTG) and normal-tension glaucoma (NTG) subgroups, using logistic regression adjusting for age and sex.

Results. In the combined NEIGHBOR-MEEI data set, significant association was observed for APOE ε4 in POAG overall (odds ratio [OR], 0.83; 95% confidence interval [CI], 0.74–0.94; P = 0.0022) and in both the HTG subgroup (OR, 0.81; 95% CI, 0.70–0.94; P = 0.0052) and NTG subgroup (OR, 0.71; 95% CI, 0.58–0.87; P = 0.0014). A rare TREM2 variant (A105V) was found only in HTG cases (3 of 2863 cases) and in none of the controls (P = 0.03). Three TREM2 rare variants associated with AD were not significantly associated with POAG (P > 0.05).

Conclusions. We have found that the APOE ε4 allele is associated with a reduced risk of POAG. Interestingly, the same allele is adversely associated with AD, suggesting a mechanistic difference between neurodegenerative diseases of the eye and the brain. TREM2 variants associated with AD did not significantly contribute to POAG risk.

Keywords: glaucoma, genetics, microglia, APOE, TREM2

Primary open-angle glaucoma (POAG) is a genetically and clinically heterogeneous neurodegenerative disease whose main hallmark is retinal ganglion cell (RGC) apoptosis. Glaucoma pathogenesis remains poorly understood, and there are currently no clinically approved therapies that directly promote RGC survival. Prior research has demonstrated that in terms of genetic risk, there exists overlap between glaucoma and neurodegenerative diseases of the brain. For example, some of the same genes that harbor known risk alleles for amyotrophic lateral sclerosis (ALS), such as optineurin (OPTN), TANK-binding kinase 1 (TBK1), and ataxin2 (ATXN2), have also been shown to confer genetic risk in glaucoma. Herein we sought to explore parallels between glaucoma and another common age-related neurodegenerative disease, Alzheimer disease (AD), which is characterized by accumulation of amyloid-β plaques, neurofibrillary tangles, neuronal loss, and inflammation.

The strongest risk factor for late-onset AD is apolipoprotein E (APOE), the major lipoprotein in the brain. APOE has three variants in humans (ε2, ε3, and ε4), which differ by two amino acid residues. The ε4 allele is the most common and is considered the baseline for AD risk; ε4 raises risk of AD relative to ε3, whereas ε2 is protective. More
recently, rare variants of the transmembrane receptor **TREM2** (triggering receptor expressed on myeloid cells 2) have also been identified as risk factors for AD.\(^\text{13-16}\) and Nasu-Hakola disease, a neurodegenerative disease characterized by early dementia and bone cysts with fractures.\(^\text{17}\) Interestingly, in the brain, **TREM2** is only expressed by myeloid cells (resident microglia and peripherally derived monocytes/macrophages),\(^\text{18}\) highlighting the importance of this cell type in the pathogenesis of AD.\(^\text{19-22}\) While **APOE** is expressed more broadly, recent work has found that **APOE** is upregulated in microglia in mouse models of neurodegenerative disease, including AD, ALS, and multiple sclerosis.\(^\text{23-25}\) Furthermore, **TREM2** and **APOE** have been identified as key regulators of the microglial molecular phenotype associated with neurodegeneration (the so-called microglial neurodegenerative or disease-associated microglia molecular signature).\(^\text{23-25}\) Given that microglia have also been implicated in the pathogenesis of glaucoma,\(^\text{26-30}\) and that **APOE** is upregulated in the retina and the aqueous humor of patients with glaucoma,\(^\text{31,32}\) we hypothesized that **APOE** and **TREM2** may have genetic associations with POAG as well.

The genetic association between **APOE** and POAG has been previously examined in a series of small and likely underpowered studies that identified conflicting results.\(^\text{33-42}\) Several meta-analyses found no association between **APOE** and glaucoma.\(^\text{43,44}\) while others reported an association between the **APOE** ε4/ε4 genotype and POAG in Asians.\(^\text{45,46}\) Another large meta-analysis reported an association between a single-nucleotide polymorphism (SNP) in the promoter region of **APOE** (rs449647) and glaucoma;\(^\text{47}\) this SNP, however, is not associated with AD.\(^\text{48}\) Interestingly, **APOE** ε4 is associated with decreased risk for another common neurodegenerative disease of the eye, age-related macular degeneration (AMD).\(^\text{49-52}\) opposite of its effect on AD. To our knowledge, the genetic association between **TREM2** and POAG has not been previously explored.

In this study, we sought to examine the associations between **APOE** and **TREM2** with POAG in a relatively large data set that includes subgroups with high-tension glaucoma (HTG) and normal-tension glaucoma (NTG). We find that **APOE** ε4 is associated with reduced risk of POAG, especially NTG. Three **TREM2** rare variants associated with AD were not significantly associated with POAG, while a rare **TREM2** variant (not implicated in AD) may contribute to HTG risk.

### Methods

#### Study Participants

This study adhered to the tenets of the Declaration of Helsinki and has been reviewed and approved by the Institutional Review Boards of the Massachusetts Eye and Ear Infirmary, Harvard School of Public Health, the Brigham and Women’s Hospital, University of Pittsburgh, Johns Hopkins University, Duke University, University of West Virginia, University of Miami, University of Michigan, Stanford University, Marsfield Clinic, and the University of California, San Diego. Informed consent was obtained from the participants after explanation of the nature and possible consequences of the study.

Two case-control genome-wide association study (GWAS) data sets were used for this study: the Mass Eye and Ear Infirmary (MEEI) component of the Glaucoma Genes and Environment (GLAUGEN) GWAS\(^\text{53}\) and the National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) GWAS.\(^\text{54}\) Detailed information on these data sets has been described previously.\(^\text{53,54}\) Briefly, the MEEI component of the GLAUGEN data set includes 486 POAG cases and 344 controls, and the NEIGHBOR data set includes 2120 POAG cases and 2262 controls. Average age of enrollment was 64.5 ± 11.0 years for MEEI GLAUGEN controls and 62.0 ± 11.2 years for the MEEI GLAUGEN cases, as well as 68.9 ± 11.4 years for the NEIGHBOR controls and 66.6 ± 13.7 years for the NEIGHBOR cases. The MEEI GLAUGEN cases and controls were 58.4% and 59.8% female, respectively, while the NEIGHBOR cases and controls were 54.1% and 56.5% female, respectively.

A harmonized definition of POAG was adopted across these data sets based on the following criteria: (1) open anterior segment angles, (2) reproducible glaucomatous visual field loss on reliable tests or (3) an eye with cup-disc ratio of at least 0.7 with one visual field showing glaucomatous loss, and (4) no identifiable secondary cause for optic nerve disease. Elevated intraocular pressure (IOP) was not a criterion for POAG definition, but if present, there had to be no secondary causes on anterior segment examination.

Sixty-seven percent of cases had a history of elevated IOP (>22 mm Hg) measured in a clinical setting (typically between the hours of 8:00 AM and 5:00 PM) and were classified as HTG. Cases with IOP <22 mm Hg (without treatment) measured in the clinic at the time of study enrollment were classified as NTG. Cases undergoing IOP-lowering therapy at the time of enrollment were included in the HTG group if they had a documented history of IOP >22 mm Hg prior to treatment, and cases undergoing IOP-lowering therapy at the time of enrollment were included in the NTG group if they did not have recorded pressures >22 mm Hg before treatment. Pretreatment IOP measurements were not available for all cases.

#### Genotyping

The MEEI and NEIGHBOR case control data sets were originally genotyped as part of the GLAUGEN and NEIGHBOR GWAS studies as previously described.\(^\text{43,44}\) Subsequently, the genotype data were used to the Haploype Reference Consortium panel\(^\text{55}\) using the Michigan Imputation Server.\(^\text{56}\) **APOE** genotypes (including alleles ε2, ε3, and ε4) were determined from haplotypes of rs492958 and rs7412 (T-T, T-C, and C-C, respectively), the two SNPs known to define **APOE** alleles. Imputation scores were high for both SNPs (r² > 0.93). Haplotypes are unambiguous from the unphased genotypes except for the double heterozygote, rs492958 C/T-rs7412 C/T, which was called ε2/ε4 rather than as ε1/ε3, since the ε1 allele is extremely rare.

Fourteen **TREM2** rare variants (minor allele frequency [MAF] <1%, call rate >98%) were extracted from Illumina HumanExome BeadArray (Illumina, Inc., San Diego, CA) genotype data for the NEIGHBORHOOD and GLAUGEN data sets. We focused on **TREM2** rare variants as those have previously been associated with AD.\(^\text{13-15}\) Genotyping was completed at the Center for Inherited Disease Research. The Illumina Genome Studio (Illumina) and PLINK\(^\text{57}\) were used for all quality controls (QC) steps except where noted. Basic QC for samples included screens for call rate (≥98.5%) and high (≥95%) concordance with a previous Illumina 660K panel run on the same sample\(^\text{58}\) where available (about 80% of samples). We verified recorded sex in the clinical records with genotyped sex by two criteria: mean fluorescence intensity on the X and Y chromosomes, plus genotype heterozygosity on the X chromosome and call rate on the Y, allowing male and female samples to have...
heterozygous X-linked and successful Y-linked genotypes, respectively. We tested samples for pairwise relationships and unexpected duplication using KING.\(^{58}\)

We verified European ancestry from the first two principal components derived from genotypes at 9000 ancestry-informative markers by means of the SNPweights program,\(^{59}\) including representative HapMap CEU, YRI, CHB, and JPT samples as reference populations. Moreover, we conducted a principal components analysis over 52,040 independent samples as reference populations. Furthermore, we conducted pairwise relationship analyses. Of the first 20 principal components, the first, sixth, and eighth were significantly associated with POAG status.

Analyses

**APOE Alleles.** Each of the three detectable APOE alleles was tested for association with glaucoma using logistic regression with age and sex as covariates. Results for ε2 and ε4 were compared to ε3 as the reference. A likelihood ratio test (LRT) was run to compare the logistic regression models that include age and sex and with or without the number of ε2 and ε4 alleles to assess the overall significance of adding APOE genotypes. APOE genotype frequencies were compared among POAG, HTG, and NTG cases and controls using the Pearson χ² test.

**TREM2 Rare Variants.** Association between individual variants and POAG case/control status was assessed using logistic regression, including as covariates age at exam, sex, and three principal components observed to be significantly associated with POAG.

### Results

In the combined NEIGHBOR-MEEI data set, APOE ε4 was inversely associated with POAG overall (odds ratio [OR], 0.83; 95% confidence interval [CI], 0.74–0.94; \(P = 0.0022\)) and in both the HTG (OR, 0.81; 95% CI, 0.70–0.94; \(P = 0.0052\)) and NTG (OR, 0.71; 95% CI, 0.58–0.87; \(P = 0.0014\)) subgroups (Table 1). The LRT, considering all alleles jointly, confirmed these findings and demonstrated the most significant difference in overall allele frequencies with NTG (\(P = 0.0041\)). The APOE allele frequencies did not

### Table 1. APOE Allelic Association With POAG, HTG, and NTG

| Allele | POAG(2120 Cases, 2262 Controls) | HTG(978 Cases, 2262 Controls) | NTG(395 Cases, 2262 Controls) |
|--------|---------------------------------|--------------------------------|--------------------------------|
|        | OR (95% CI) P Value             | OR (95% CI) P Value             | OR (95% CI) P Value             |
| ε2     | 0.96 (0.83–1.13) 0.05           | 0.94 (0.77–1.15) 0.57           | 1.09 (0.83–1.42) 0.52           |
| ε4     | 0.84 (0.74–0.96) 0.0078         | 0.81 (0.68–0.97) 0.013           | 0.69 (0.54–0.88) 0.0036         |
| LRT    | 0.021                           | 0.03                           | 0.0099                          |

**NEIGHBOR**

| Allele | POAG(486 Cases, 344 Controls) | HTG(320 Cases, 344 Controls) | NTG(166 Cases, 344 Controls) |
|--------|--------------------------------|--------------------------------|--------------------------------|
|        | OR (95% CI) P Value             | OR (95% CI) P Value             | OR (95% CI) P Value             |
| ε2     | 1.08 (0.74–1.60) 0.68           | 1.18 (0.77–1.79) 0.45           | 0.94 (0.54–1.59) 0.82           |
| ε4     | 0.81 (0.60–1.10) 0.18           | 0.81 (0.58–1.13) 0.22           | 0.81 (0.53–1.20) 0.30           |
| LRT    | 0.39                           | 0.38                           | 0.55                           |

**MEEI**

| Allele | POAG(2606 Cases, 2606 Controls) | HTG(1298 Cases, 2606 Controls) | NTG(561 Cases, 2606 Controls) |
|--------|---------------------------------|--------------------------------|--------------------------------|
|        | OR (95% CI) P Value             | OR (95% CI) P Value             | OR (95% CI) P Value             |
| ε2     | 0.97 (0.84–1.12) 0.70           | 0.98 (0.81–1.17) 0.80           | 1.01 (0.80–1.28) 0.92           |
| ε4     | 0.83 (0.74–0.94) 0.0022         | 0.81 (0.70–0.94) 0.0052         | 0.71 (0.58–0.87) 0.0014         |
| LRT    | 0.0067                          | 0.02                           | 0.0041                          |

**Combined data set**

| Allele | POAG(486 Cases, 344 Controls) | HTG(320 Cases, 344 Controls) | NTG(166 Cases, 344 Controls) |
|--------|--------------------------------|--------------------------------|--------------------------------|
|        | OR (95% CI) P Value             | OR (95% CI) P Value             | OR (95% CI) P Value             |
| ε2     | 0.97 (0.84–1.12) 0.70           | 0.98 (0.81–1.17) 0.80           | 1.01 (0.80–1.28) 0.92           |
| ε4     | 0.83 (0.74–0.94) 0.0022         | 0.81 (0.70–0.94) 0.0052         | 0.71 (0.58–0.87) 0.0014         |
| LRT    | 0.0067                          | 0.02                           | 0.0041                          |
significantly differ among POAG cases and controls when grouped according to age (Fig. 1).

The distribution of APOE genotypes among POAG overall, HTG, and NTG cases and controls differed significantly, with the largest effect observed for the NTG case versus control comparison (P = 0.008; POAG, P = 0.02 and HTG, P = 0.085) (Fig. 2).

To determine whether the ε4 allele is associated with delayed age of disease onset, we compared the mean age of diagnosis for the ε3/ε3 POAG cases with the mean age of diagnosis for the ε3/ε4 POAG cases. While the mean (65.8 vs. 64.9 years) and median (67.3 vs. 65.6 years) ages of onset were indeed greater in the ε3/ε4 cases than in ε3/ε3 cases, the difference was not significant (P = 0.14 by t test, P = 0.13 by Wilcoxon rank-sum test), likely due to limited sample size (463 ε3/ε4 POAG cases).

TREM2 is known to interact with APOE, and rare TREM2 coding variants have been associated with AD.13–15 To determine whether any rare TREM2 coding variants are associated with POAG, we extracted NEIGHBOR and MEEI case-control association data for variants genotyped using the Human Exome bead array. Seven rare (MAF <1%) TREM2 missense variants were identified, and one variant (A105V) was identified in three HTG cases and in no controls (P = 0.008) (Table 2). Comparing the HTG allele frequency to the European Caucasian population in population database ing AD, ALS, and multiple sclerosis.23,24 Furthermore, TREM2 has been found to be a critical regulator of this microglial neurodegenerative phenotype that develops in response to apoptotic neurons.53 We speculate that the strength of association noted between APOE ε4 and POAG will depend on the proportion of NTG patients enrolled in a given study, which may explain some of the variability in the published individual studies.33–42 and meta-analyses.43–47

What is the mechanism by which APOE ε4 may be protective in glaucoma? APOE is expressed in a variety of cell types in the healthy retina and the optic nerve, including Müller glia and astrocytes.54 However, APOE is also upregulated in the neurodegeneration-associated microglia in the brain in a variety of neurodegenerative disease mouse models, including AD, ALS, and multiple sclerosis.55,56 Furthermore, APOE has been found to be a critical regulator of this microglial neurodegenerative phenotype that develops in response to apoptotic neurons.53 We speculate that APOE may be similarly upregulated in microglia in glaucoma, as microglial reactivity has been found to contribute to glaucoma pathogenesis.56–60

Another interesting parallel can be made between our findings and the association of APOE with AMD, where APOE ε4 has also been found to be inversely associated with disease.69–72 The reason why the same APOE allele has an opposing relationship in ocular neurodegenerative diseases and AD is presently poorly understood. A study by Levy et al.63 has shown that in a mouse model of AMD, mice...
| rsID       | Variant | CADD | PP   | SIFT | gnomAD(MAF) | Controls(MAF) | POAG(MAF) | HTG(MAF) | NTG(MAF) | P  | P'  |
|------------|---------|------|------|------|-------------|---------------|------------|----------|----------|----|-----|
| rs20392967 | D39E    | 23.4 | PS   | D    | 1.3E-4      | 1/6381 (1.5E-4) | 0/5628 (0.00) | 0/2866 (0.00) | 0/1158 (0.00) | 0.99 | 0.99 |
| rs143332484| R62H‡   | 11.1 | B    | T    | 0.012       | 69/6347 (0.011) | 49/5623 (0.009) | 30/2836 (0.011) | 10/1148 (0.009) | 0.24 | 0.06 |
| rs142232675| D87N‡   | 22.8 | PD   | T    | 0.002       | 4/6412 (6.2E-4) | 4/5668 (7.1E-4) | 0/2866 (0.00)   | 1/1157 (8.6E-4) | 0.86 | 0.008|
| rs145080001| A105V   | 24.2 | PD   | D    | 1.3E-4      | 0/6416 (0.00)  | 3/5669 (5.3E-4) | 3/2863 (1.0E-3) | 0/1158 (0.00)   | 0.07 | (POAG)0.03 (HTG) 0.05 (POAG)0.008 (HTG) |
| rs149622783| R156Q   | 1.84 | B    | T    | 1.3E-4      | 2/6414 (3.1E-4) | 3/5669 (5.3E-4) | 1/2865 (3.5E-4) | 1/1157 (8.6E-4) | 0.56 | 0.05 |
| rs79011726 | E151K   | 23.2 | B    | T    | 1.8E-4      | 3/6413 (4.7E-4) | 1/5671 (1.8E-4) | 0/2866 (0.00)   | 0/1158 (0.00)   | 0.29 | 0.99 |
| rs2234255  | H157Y‡  | 23.1 | PS   | D    | 2.9E-4      | 3/6413 (4.7E-4) | 2/5670 (3.5E-4) | 0/2866 (0.00)   | 1/1157 (8.6E-4) | 0.76 | 0.67 |

B, benign; CADD, combined annotation-dependent depletion score; D, damaging; PD, probably damaging; PP, polyphen2; PS, possibly damaging; SIFT, sorting intolerant from tolerant score; T, tolerated.

* P value for logistic regression using cases and controls. Cases are POAG overall except for A105V, where the results are provided for both POAG overall and HTG.

† Comparison of POAG cases to the European population distribution in GnomAD using the Fisher exact test. For A105V, the results are provided for both POAG and HTG.

‡ Previously associated with AD.13–16
with human APOE ε4 allele had lower levels of Monocyte chemoattractant protein-1 (MCP-1/CCL2) (a major monocyte attractant), less myeloid cell accumulation in the subretinal space, and decreased photoreceptor degeneration. Therefore, microglia with the APOE ε4 allele appear to be less reactive, which may be helpful in retinal neurodegenerations but harmful in AD, which is characterized by toxic Aβ plaques and tau deposits that need to be contained by the immune system. Furthermore, there could be additional mechanisms by which APOE plays a role in AD pathogenesis that are unrelated to its effect on the microglial transcriptional phenotype. For instance, APOE stimulates production of the Aβ precursor Amyloid precursor protein (APP) and thus directly contributes to Aβ plaque formation, with ε4 allele being most potent at producing this effect.64

We also investigated the association between glaucoma and TREM2, a transmembrane receptor expressed by myeloid cells that has recently been associated with AD.20–22 We have found that rare variants previously associated with AD interrogated by our exome chip (R62H,13,14 D87N,15 and H157Y14,16) were not associated with POAG, which further underscores different underlying pathogenic mechanisms in glaucoma and AD. Notably, unlike APOE ε4, TREM2 rare variants were also not associated with NTG. Although both APOE and TREM2 have been implicated in the regulation of the microglial neurodegeneration-associated phenotype, single-cell RNAseq analysis in a mouse model of AD has found that TREM2 and APOE may regulate different subpopulations of neurodegeneration-associated microglia.24 Whether TREM2 plays a role in regulating microglial molecular signature in the retina will merit further investigation.

An unexpected finding of our study was the association of one rare variant of TREM2, A105V, with HTG, although our data set is the largest of its kind, its statistical significance was not high enough to warrant further study in animal glaucoma models (for instance, in APOE ε2, ε3, and ε4 humanized mice, which are commercially available). Interestingly, TREM2 rare variants associated with AD did not contribute to POAG risk in our study. The association between a different rare variant of TREM2, A105V, with HTG is intriguing but at this point preliminary and warrants further study and validation in larger data sets.

Acknowledgments

Presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Vancouver, Canada, April 29th 2019.

Supported by MEE P30 (NIH/NEI EY014104); NIH/NEI R01 EY022305 (JLW); NIH/NEI K12 EY016355 (MAM); NIH/NEI K08 EY030160 (MAM); American Glaucoma Society Young Clinician Scientist Award (AM); Research to Prevent Blindness Career Development Award (MAM); NIH/NEI R01 EY015473 (LRP); NIH/NINDS R01 NS088137 (OB), R21 NS104609 (OB), R21 NS101673 (OB), NIH/NIA R01 AG051812 (OB), and R01 AG054672 (OB); NIH/NEI R01 EY027921 (OB); National Multiple Sclerosis Society (5092A1) (OB); National Health and Medical Research Council Australia (RG180378) (OB); Nancy Davis Foundation Faculty Award (OB); Cure Alzheimer's Fund Award (OB); and Amyotrophic Lateral Sclerosis Association Award (OB).

Disclosure: M.A. Margeta, None; S.M. Letcher, None; R.P. Igo Jr., None; J.N. Cooke Bailey, None; L.R. Pasquale, Verily (C), Nicox (C), Emerald Bioscience (C), Eyenovia (C), and Bausch+Lomb (C); J.L. Haines, None; O. Butovsky, None; J.L. Wiggs, None

References

1. Almasieh M, Levin LA. Neuroprotection in glaucoma: animal models and clinical trials. Annu Rev Vis Sci. 2017;3:91–120.
2. Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295:1077–1079.
3. Kawase K, Allingham RR, Meguro A, et al. Confirmation of TBK1 duplication in normal tension glaucoma. Exp Eye Res. 2012;96:178–180.
4. Bailey JN, Loomis SJ, Kang JH, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016;48:189–194.
5. Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:225–226.
6. Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436–1441.
7. Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069–1075.
8. Lee T, Li YR, Ingre C, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet. 2011;20:1697–1700.
9. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.
10. Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011;3:77rs71.
11. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923.
Association of APOE and TREM2 With Glaucoma

12. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1993;7:180–184.

13. Jin SC, Benitez BA, Karch CM, et al. Coding variants in TREM2 increase risk for Alzheimer’s disease. Hum Mol Genet. 2014;23:5838–5846.

14. Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PCLG2, AB13, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet. 2017;49:1373–1384.

15. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–127.

16. Jiang T, Hou JK, Gao Q, et al. TREM2 p.H157Y variant and the risk of Alzheimer’s disease: a meta-analysis involving 14,510 subjects. Curr Neurovasc Res. 2016;13:318–320.

17. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:650–662.

18. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445–453.

19. Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212:287–295.

20. Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases. Trends Mol Med. 2017;23:512–533.

21. Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the role of TREM2 in Alzheimer’s disease. Neuron. 2017;94:287–298.

22. Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17:201–207.

23. Krasemann S, Madore C, Calic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566–581.e569.

24. Keren-Shaul H, Spindler A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169:1276–1290.e1217.

25. Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci. 2018;19:622–635.

26. Neufeld AH. Microglia in the optic nerve head and the region of parapapillary choroidal atrophy in glaucoma. Arch Ophthalmol. 1999;117:1050–1056.

27. Yuan L, Neufeld AH. Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res. 2001;64:523–532.

28. Bosco A, Steele MR, Vetter ML. Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol. 2011;519:599–620.

29. Chidlow G, Ehninger A, Wood JP, Casson RJ. Evidence supporting an association between expression of major histocompatibility complex II by microglia and optic nerve degeneration during experimental glaucoma. J Glaucoma. 2016;25:681–691.

30. Bosco A, Inman DM, Steele MR, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2008;49:1437–1446.

31. Mirzaei M, Gupta VB, Chick JM, et al. Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes. Sci Rep. 2017;7:12685.

32. Inoue T, Kawaji T, Tanhara H. Elevated levels of multiple biomarkers of Alzheimer’s disease in the aqueous humor of eyes with open-angle glaucoma. Invest Ophthalmol Vis Sci. 2013;54:5353–5358.

33. Mabuchi F, Tang S, Ando D, et al. The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population. Mol Vis. 2005;11:609–612.

34. Lam CY, Fan BJ, Wang DY, et al. Association of apolipoprotein E polymorphisms with normal tension glaucoma in a Chinese population. J Glaucoma. 2006;15:218–222.

35. Al-Dabbagh NM, Al-Dhayani N, Arfin M, Tariq M. Apolipoprotein E polymorphisms and primary glaucoma in Saudis. Mol Vis. 2009;15:912–919.

36. Vickers JC, Craig JE, Stankovich J, et al. The apolipoprotein epsilon4 gene is associated with elevated risk of normal tension glaucoma. Mol Vis. 2002;8:389–393.

37. Junemann A, Bleich S, Reulbach U, et al. Prospective case control study on genetic association of apolipoprotein epsilon2 with intraocular pressure. Br J Ophthalmo. 2004;88:581–582.

38. Ressinotis T, Griffiths PG, Birch M, Keers S, Chinnery PF. The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma. Arch Ophthalmol. 2004;122:258–261.

39. Lake S, Liverani E, Desai M, et al. Normal tension glaucoma is not associated with the common apolipoprotein E gene polymorphisms. Br J Ophthalmol. 2004;88:491–493.

40. Zetterberg M, Tasa G, Palmer MS, et al. Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. Am J Ophthalmol. 2007;143:1059–1060.

41. Saglar E, Yucel D, Bozkurt B, Ozgul RK, Irkem C, Ogus A. Association of polymorphisms in APOE, p53, and p21 with primary open-angle glaucoma in Turkish patients. Mol Vis. 2009;15:1270–1276.

42. Yuilacigolu Tuncay F, Aktas Z, Ergun MA, Ergun SG, Hasanreisoglu M, Hasanreisoglu B. Association of polymorphisms in APOE and LOXL1 with pseudoexfoliation syndrome and pseudoexfoliation glaucoma in a Turkish population. Ophthalimic Genet. 2017;38:95–97.

43. Song Q, Chen P, Liu Q. Role of the APOE epsilon2/epsilon3/epsilon4 polymorphism in the development of primary open-angle glaucoma: evidence from a comprehensive meta-analysis. PLoS One. 2013;8:e82347.

44. Wang Y, Zhou M, Huang W, Chen S, Zhang X. Lack of association of apolipoprotein E (ApoE) epsilon2/epsilon3/epsilon4 polymorphisms with primary open-angle glaucoma: a meta-analysis from 1916 cases and 1756 controls. PLoS One. 2013;8:e72644.

45. Wang Y, Zhou YF, Zhao BY, Gu ZY, Li SL. Apolipoprotein E gene epsilon4 polymorphism is associated with elevated risk of primary open angle glaucoma in Asians: a meta-analysis. BMC Med Genet. 2014;15:60.

46. Liao R, Ye M, Xu X. An updated meta-analysis: apolipoprotein E genotypes and risk of primary open-angle glaucoma. Mol Vis. 2014;20:1025–1036.

47. Chen M, Yu X, Xu J, et al. Association of gene polymorphisms with primary open angle glaucoma: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2019;60:1105–1121.

48. Xiao H, Gao Y, Liu L, Li Y. Association between poly- morphisms in primary open-angle glaucoma. Br J Ophthalmol. 2004;88:581–582.

49. Al-Dabbagh NM, Al-Dhayani N, Arfin M, Tariq M. Apolipoprotein E polymorphisms and primary glaucoma in Saudis. Mol Vis. 2009;15:912–919.

50. Vickers JC, Craig JE, Stankovich J, et al. The apolipoprotein epsilon4 gene is associated with elevated risk of normal tension glaucoma. Mol Vis. 2002;8:389–393.

51. Junemann A, Bleich S, Reulbach U, et al. Prospective case control study on genetic association of apolipoprotein epsilon2 with intraocular pressure. Br J Ophthalmo. 2004;88:581–582.
50. Schmidt S, Klaver C, Saunders A, et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. *Ophthalmic Genet*. 2002;23:209–223.
51. Baird PN, Guida E, Chu DT, Vu HT, Guymer RH. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2004;45:1311–1315.
52. McKay GJ, Patterson CC, Chakravarthy U, et al. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. *Hum Mutat*. 2011;32:1407–1416.
53. Wiggs JL, Kang JH, Yaspan BL, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in Caucasians from the USA. *Hum Mol Genet*. 2011;20:4707–4713.
54. Wiggs JL, Yaspan BL, Hauser MA, et al. Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. *PLoS Genet*. 2012;8:e1002654.
55. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48:1279–1283.
56. Das S, Forer L, Schonherr S, et al. Next-generation genotype imputation service and methods. *Nat Genet*. 2016;48:1284–1287.
57. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81:559–575.
58. Manichaikul A, Mychaleckyj JC, Rich SS, Daly M, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. *Bioinformatics*. 2010;26:2867–2873.
59. Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL. Improved ancestry inference using weights from external reference panels. *Bioinformatics*. 2013;29:1399–1406.
60. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006;38:904–909.
61. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. *Ophthalmoiology*. 2004;111:1641–1648.
62. Omodaka K, Nishiguchi KM, Yasuda M, et al. Neuroprotective effect against axonal damage-induced retinal ganglion cell death in apolipoprotein E-deficient mice through the suppression of kainate receptor signaling. *Brain Res*. 2014;1586:203–212.
63. Levy O, Lavalette S, Hu SJ, et al. APOE isoforms control pathogenic subretinal inflammation in age-related macular degeneration. *J Neurosci*. 2015;35:13568–13576.
64. Huang YA, Zhou B, Wernig M, Sudhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβeta secretion. *Cell*. 2017;168:427–441.e421.
65. Margota MA, Lad EM, Proia AD. CD163+ macrophages infiltrate axon bundles of postmortem optic nerves with glaucoma. *Graefes Arch Clin Exp Ophthalmol*. 2018;256:2449–2456.
66. Alvarado JA, Katz LJ, Trivedi S, Shifera AS. Monocyte modulation of aqueous outflow and recruitment to the trabecular meshwork following selective laser trabeculoplasty. *Arch Ophthalmol*. 2010;128:731–737.
67. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Lencz TK, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581:434–443.